10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
46.27
-1.79 (-3.72%)
At close: Jul 24, 2026, 4:00 PM EDT
46.01
-0.26 (-0.56%)
After-hours: Jul 24, 2026, 7:57 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, 10x Genomics stock has a consensus rating of "Buy" and an average price target of $41.54. The average 1-year stock price forecast is 10.22% lower than the current stock price, while the lowest is $25 (-45.97%) and the highest is $50 (+8.06%).
Price Target: $41.54 (-10.22%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 12 | 10 | 10 | 10 | 10 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Maintains $20 → $38 | Hold | Maintains | $20 → $38 | -17.87% | Jul 22, 2026 |
| Leerink Partners | Leerink Partners | Hold Reiterates $23 → $40 | Hold | Reiterates | $23 → $40 | -13.55% | Jul 17, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $25 → $47 | Hold | Maintains | $25 → $47 | +1.58% | Jul 15, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $32 → $50 | Buy | Reiterates | $32 → $50 | +8.06% | Jul 14, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $22 → $37 | Hold | Maintains | $22 → $37 | -20.03% | Jul 9, 2026 |
Financial Forecast
Revenue This Year
614.06M
from 642.82M
Decreased by -4.47%
Revenue Next Year
671.47M
from 614.06M
Increased by 9.35%
EPS This Year
n/a
from 0.12
Decreased by -100.00%
EPS Next Year
0.21
EPS and Forward PE are based on non-GAAP adjusted numbers.